• Cytosolic DNA Accumulation Regulates TDP-43 Homeostasis in N

  2026-07-08

  This study uncovers how cytosolic DNA accumulation drives pathological changes in TAR DNA-binding protein 43 (TDP-43), a key player in neurodegenerative diseases such as ALS. Through a combination of cell models and molecular assays, the authors demonstrate that persistent cytosolic DNA triggers TDP-43 mislocalization and aggregation, providing new mechanistic insight into TDP-43 proteinopathy and its links to DNA damage response.

• Pifithrin-α: p53 Inhibitor Workflows for Neurotoxicity & Apo

  2026-07-08

  Pifithrin-α (PFTα) is a gold-standard p53 inhibitor enabling targeted dissection of apoptosis and ferroptosis mechanisms in neurotoxicity and cancer research. Discover how this tool empowers reproducible, high-impact workflows and troubleshooting strategies for translational studies—especially in modeling p53-mediated cell death after toxicant exposure.

• N-MYC–eIF4G1 Axis Drives Survival in inv(16) AML Cells

  2026-07-07

  This study uncovers a novel regulatory axis in acute myeloid leukemia (AML) with chromosome inversion inv(16), demonstrating that N-MYC overexpression sustains leukemic cell survival through transcriptional activation of eIF4G1. The findings establish a new mechanistic rationale for targeting the N-MYC/eIF4G1 pathway in myeloid leukemia and clarify how specific epigenetic regulators contribute to disease maintenance.

• Epidermal Growth Factor in 3D Spheroid Assays: Applied Proto

  2026-07-07

  Harness recombinant human EGF for rigorous, high-throughput assessment of cell proliferation and stemness using 3D tumor spheroid models. Discover precise experimental parameters, troubleshooting insights, and advanced applications—anchored in recent workflow innovations and APExBIO's high-purity standards.

• Pharmacogenomics of Chloroquine: Genetic Variants Impact Eff

  2026-07-06

  This article reviews recent evidence on how genetic polymorphisms in cytochrome P450 enzymes influence the metabolism, efficacy, and toxicity of chloroquine. The findings highlight the need for pharmacogenomic consideration in research and clinical applications, especially for malaria and autoimmune disease studies.

• JAK Inhibitors and Endothelial Dysfunction: Comparative Vasc

  2026-07-06

  This study systematically compared the effects of various approved JAK inhibitors, including tofacitinib citrate, on endothelial cell inflammation and prothrombotic changes during cytokine-driven stress. The findings reveal that while all tested JAK inhibitors reduced inflammatory cytokine release, their impacts on adhesion molecules and procoagulant pathways varied, with important implications for cardiovascular safety in immune regulation research.

• Pertussis Toxin in Immune Modulation: Applied Workflows & Ti

  2026-07-05

  Unlock the full potential of APExBIO’s Pertussis toxin for dissecting cAMP signaling and immune response modulation in both in vitro and in vivo models. This article delivers actionable protocols, troubleshooting strategies, and evidence-driven insights, empowering researchers to drive reliability and depth in immunological assays.

• ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-07-04

  This study elucidates how ETS1 regulates mitophagy in bronchopulmonary dysplasia (BPD) by targeting the SENP2/HSPA8/FUNDC1 axis and modulating SUMO1-dependent posttranslational modification. The findings highlight a novel transcriptional mechanism linking sumoylation dynamics to mitochondrial quality control, suggesting targeted sumoylation inhibition as a promising research avenue in neonatal lung disease.

• Naftifine HCl: Mechanistic Precision in Translational Antifu

  2026-07-03

  This thought-leadership article examines Naftifine HCl, an allylamine antifungal agent, through the lens of molecular mechanism, translational research, and strategic assay design. Drawing on recent advances in cell signaling and muscle biology, it highlights opportunities for researchers to expand the utility of Naftifine HCl beyond conventional topical antifungal treatment, while situating APExBIO's high-purity reagent within a competitive and innovative research landscape.

• SAR405: Precision Vps34 Inhibitor for Autophagy Assays

  2026-07-03

  SAR405 offers researchers nanomolar precision and exquisite selectivity for dissecting autophagy and vesicle trafficking. Its compatibility with advanced cell models and synergy with mTOR inhibitors empower robust, reproducible autophagy inhibition workflows.

• Cell Cycle Assay Kit: Mechanistic Precision for Translationa

  2026-07-02

  Explore how the Cell Cycle Assay Kit (K2263) empowers translational researchers to decode cell cycle dynamics, apoptosis, and therapeutic responses in cancer models. This thought-leadership article blends mechanistic insight, real-world workflow guidance, and strategic outlook, bridging evidence from recent lymphoma research and advanced PI/RNase protocols for cutting-edge cell cycle progression analysis.

• Propranolol in Emotional Memory Modulation: Scientific Insig

  2026-07-02

  Explore the unique role of Propranolol as a non-selective β-adrenergic receptor blocker in emotional memory modulation. This article delves into the neuroscience behind its effects, protocol considerations, and the translational significance for psychiatric research, providing a perspective beyond traditional cardiovascular applications.

• Enhanced ECL Chemiluminescent Substrate Kit: Sensitivity & U

  2026-07-01

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) enables ultra-sensitive western blot chemiluminescence detection and robust antibody assays. This APExBIO product achieves low-picogram protein quantification with minimal background and broad imaging compatibility.

• Trilaurin (Glycerol Tridodecanoate): Enabling Advanced Drug

  2026-07-01

  Trilaurin stands out as a multifunctional lipid excipient, empowering both sustainable biocatalytic synthesis and next-generation oral drug delivery systems. Its proven roles in enzyme-driven fatty amine production and colon-targeted nanotherapeutics set new standards for bench-to-bedside translational research.

• Birinapant (TL32711): Precision Tools for Overcoming Cancer

  2026-06-30

  Explore the integration of Birinapant (TL32711) in translational cancer research, leveraging mechanistic insights into IAP antagonism, apoptosis induction, and emerging biomarkers such as MDM1 to address chemoradiotherapy resistance. This article offers strategic guidance for researchers navigating the evolving landscape of apoptosis-targeting therapeutics.

452 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page